Covance (NYSE: CVD ) is expected to report Q1 earnings on May 1. Here's what Wall Street wants to see:
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Covance's revenues will increase 7.3% and EPS will increase 20.0%.
The average estimate for revenue is $569.3 million. On the bottom line, the average EPS estimate is $0.72.
Last quarter, Covance reported revenue of $562.2 million. GAAP reported sales were 5.6% higher than the prior-year quarter's $532.5 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $0.73. GAAP EPS of $0.61 for Q4 were 79% higher than the prior-year quarter's $0.34 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 28.9%, 130 basis points worse than the prior-year quarter. Operating margin was 8.8%, 10 basis points worse than the prior-year quarter. Net margin was 6.0%, 200 basis points better than the prior-year quarter.
The full year's average estimate for revenue is $2.34 billion. The average EPS estimate is $3.04.
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 311 members out of 319 rating the stock outperform, and eight members rating it underperform. Among 110 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 109 give Covance a green thumbs-up, and one give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Covance is outperform, with an average price target of $54.88.
Looking for alternatives to Covance? It takes more than great companies to build a fortune for the future. Learn the basic financial habits of millionaires next door and get focused stock ideas in our free report, "3 Stocks That Will Help You Retire Rich." Click here for instant access to this free report.
- Add Covance to My Watchlist.